Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer.
Zhang C, Zhou F, Zou J, Fang Y, Liu Y, Li L, Hou J, Wang G, Wang H, Lai X, Xie L, Jiang J, Yang C, Huang Y, Chen Y, Zhang H, Li Y.
Zhang C, et al. Among authors: zhou f.
Front Oncol. 2024 Jan 16;13:1322078. doi: 10.3389/fonc.2023.1322078. eCollection 2023.
Front Oncol. 2024.
PMID: 38293701
Free PMC article.
Review.